{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:27:32Z","timestamp":1792056452301,"version":"4.4.0"},"reference-count":69,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with multiple myeloma (MM) are at an increased risk of venous and arterial thrombosis. The pathogenesis remains unclear, but probably involves several factors such as activation of procoagulant factors, acquired activated protein C resistance, and inflammation. In addition to general risk factors for venous thromboembolism, such as older age, immobility, surgery, and inherited thrombophilia, there are some MM-specific and treatment-related factors that contribute to the increased risk. The risk for venous thromboembolism is high when patients are treated with thalidomide or lenalidomide in combination with dexamethasone or multi-agent chemotherapy. Thromboprophylaxis should be given in these settings. Which agent is the most appropriate is a matter of debate, but aspirin, low-molecular-weight heparin, and warfarin all seem to be effective. This review discusses risk factors for thromboembolism in MM and general, disease-specific and treatment-related mechanisms for thrombosis. Recommendations for thromboprophylaxis are described and treatment choices for venous thrombosis in MM patients are reviewed.<\/jats:p>","DOI":"10.1182\/asheducation-2010.1.437","type":"journal-article","created":{"date-parts":[[2011,1,16]],"date-time":"2011-01-16T19:08:48Z","timestamp":1295204928000},"page":"437-444","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":83,"title":["Thrombosis in Multiple Myeloma"],"prefix":"10.1182","volume":"2010","author":[{"given":"Sigurdur Yngvi","family":"Kristinsson","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111716545353200_B1","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1136\/bmj.3.5720.438","article-title":"Thromboembolic complications in myelomatosis","volume":"3","author":"Catovsky","year":"1970","journal-title":"Br Med J"},{"key":"2019111716545353200_B2","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"2019111716545353200_B3","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"2019111716545353200_B4","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1056\/NEJM200106213442516","article-title":"Deep venous thrombosis and thalidomide therapy for multiple myeloma","volume":"344","author":"Osman","year":"2001","journal-title":"N Engl J Med"},{"key":"2019111716545353200_B5","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.4065\/80.12.1568","article-title":"The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma","volume":"80","author":"Baz","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"2019111716545353200_B6","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"key":"2019111716545353200_B7","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1182\/blood-2008-04-151076","article-title":"Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"112","author":"Kristinsson","year":"2008","journal-title":"Blood"},{"key":"2019111716545353200_B8","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1182\/blood-2009-11-252072","article-title":"Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study","volume":"115","author":"Kristinsson","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2019111716545353200_B9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2009-12-257519","article-title":"High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study","volume":"116","author":"Libourel","year":"2010","journal-title":"Blood"},{"key":"2019111716545353200_B10","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"2019111716545353200_B11","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/archinte.160.6.809","article-title":"Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study","volume":"160","author":"Heit","year":"2000","journal-title":"Arch Intern Med"},{"key":"2019111716545353200_B12","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1200\/JCO.2009.22.8197","article-title":"Venous thromboembolism in the hematologic malignancies","volume":"27","author":"Falanga","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019111716545353200_B13","doi-asserted-by":"crossref","first-page":"955","DOI":"10.7326\/0003-4819-137-12-200212170-00008","article-title":"Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism","volume":"137","author":"Prandoni","year":"2002","journal-title":"Ann Intern Med"},{"key":"2019111716545353200_B14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/asheducation-2009.1.259","article-title":"Risk of future arterial cardiovascular events in patients with idiopathic venous thromboembolism","author":"Green","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2019111716545353200_B15","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1182\/blood-2009-08-239046","article-title":"Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients","volume":"115","author":"Gay","year":"2010","journal-title":"Blood"},{"key":"2019111716545353200_B16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2141.2008.07577.x","article-title":"Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias","volume":"145","author":"Eby","year":"2009","journal-title":"Br J Haematol"},{"key":"2019111716545353200_B17","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1056\/NEJMc053530","article-title":"Lenalidomide and venous thrombosis in multiple myeloma","volume":"354","author":"Knight","year":"2006","journal-title":"N Engl J Med"},{"key":"2019111716545353200_B18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"2019111716545353200_B19","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2006.09.0100","article-title":"Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003","volume":"25","author":"Kristinsson","year":"2007","journal-title":"J Clin Oncol"},{"key":"2019111716545353200_B20","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.leukres.2007.12.002","article-title":"Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens","volume":"32","author":"van Marion","year":"2008","journal-title":"Leuk Res"},{"key":"2019111716545353200_B21","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2141.2006.06208.x","article-title":"Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism","volume":"134","author":"Elice","year":"2006","journal-title":"Br J Haematol"},{"key":"2019111716545353200_B22","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"key":"2019111716545353200_B23","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/j.1538-7836.2007.02542.x","article-title":"Thalidomide causes platelet activation, which can be abrogated by aspirin","volume":"5","author":"Dunkley","year":"2007","journal-title":"J Thromb Haemost"},{"key":"2019111716545353200_B24","first-page":"3349","article-title":"Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2","volume":"7","author":"Fujita","year":"2001","journal-title":"Clin Cancer Res"},{"key":"2019111716545353200_B25","doi-asserted-by":"crossref","first-page":"4924","DOI":"10.1182\/blood-2008-02-140434","article-title":"Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping","volume":"112","author":"Johnson","year":"2008","journal-title":"Blood"},{"key":"2019111716545353200_B26","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.thromres.2007.06.013","article-title":"Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro","volume":"121","author":"Avcu","year":"2008","journal-title":"Thromb Res"},{"key":"2019111716545353200_B27","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1182\/blood-2004-03-0928","article-title":"Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B","volume":"105","author":"Sohn","year":"2005","journal-title":"Blood"},{"key":"2019111716545353200_B28","first-page":"114","article-title":"A phase III study of enoxaparin vs aspirin vs low-dose warfarin as thromboprophylaxis for newly diagnosed myeloma patients treated with thalidomide based-regimens","author":"Palumbo","year":"2009","journal-title":"Blood"},{"key":"2019111716545353200_B29","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1182\/blood.V114.22.350.350","article-title":"A prospective, randomized study of melphalan, prednisone, lenalidomide (MPR) versus Melphalan (200 Mg\/M2) and autologous transplantation (Mel200) in newly diagnosed myeloma patients: an interim analysis [abstract]","volume":"114","author":"Palumbo","year":"2009","journal-title":"Blood"},{"key":"2019111716545353200_B30","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0140-6736(00)02110-3","article-title":"Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"2019111716545353200_B31","doi-asserted-by":"crossref","first-page":"381S","DOI":"10.1378\/chest.08-0656","article-title":"Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Geerts","year":"2008","journal-title":"Chest"},{"key":"2019111716545353200_B32","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.2106\/JBJS.I.00511","article-title":"American academy of orthopaedic surgeons clinical practice guideline on. Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty","volume":"91","author":"Johanson","year":"2009","journal-title":"J Bone Joint Surg Am"},{"key":"2019111716545353200_B33","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/ajh.20625","article-title":"Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis","volume":"81","author":"Ikhlaque","year":"2006","journal-title":"Am J Hematol"},{"issue":"1","key":"2019111716545353200_B34","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1365-2141.2010.08207.x","article-title":"Monoclonal gammopathy of undetermined significance: a consensus statement","volume":"150","author":"Berenson","year":"2010","journal-title":"Br J Haematol"},{"key":"2019111716545353200_B35","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00277-008-0561-1","article-title":"Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone","volume":"88","author":"Klein","year":"2009","journal-title":"Ann Hematol"},{"key":"2019111716545353200_B36","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/sj.bmt.1704952","article-title":"Safety of low-dose low-molecular-weight-heparins in thrombocytopenic stem cell transplantation patients: a case series and review of the literature","volume":"35","author":"Ibrahim","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"2019111716545353200_B37","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/j.1538-7836.2008.03055.x","article-title":"Testing for inherited thrombophilia does not reduce the recurrence of venous thrombosis","volume":"6","author":"Coppens","year":"2008","journal-title":"J Thromb Haemost"},{"key":"2019111716545353200_B38","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1365-2141.2004.05078.x","article-title":"Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation","volume":"126","author":"Zangari","year":"2004","journal-title":"Br J Haematol"},{"key":"2019111716545353200_B39","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"2019111716545353200_B40","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/MBC.0b013e3281067fb2","article-title":"Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients","volume":"18","author":"Zangari","year":"2007","journal-title":"Blood Coagul Fibrinolysis"},{"key":"2019111716545353200_B41","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1200\/JCO.2009.23.0169","article-title":"Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone","volume":"28","author":"Zangari","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111716545353200_B42","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1365-2796.2010.02242.x","article-title":"New aspects on treatment modalities for thromboembolic episodes","volume":"268","author":"Schulman","year":"2010","journal-title":"J Intern Med"},{"key":"2019111716545353200_B43","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99\u201306): a randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"key":"2019111716545353200_B44","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"key":"2019111716545353200_B45","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","article-title":"Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01\/01 trial","volume":"27","author":"Hulin","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019111716545353200_B46","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","article-title":"Thalidomide alone or with dexamethasone for previously untreated multiple myeloma","volume":"21","author":"Weber","year":"2003","journal-title":"J Clin Oncol"},{"key":"2019111716545353200_B47","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/sj.leu.2402866","article-title":"Thalidomide as initial therapy for early-stage myeloma","volume":"17","author":"Rajkumar","year":"2003","journal-title":"Leukemia"},{"key":"2019111716545353200_B48","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V98.2.492","article-title":"Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients","volume":"98","author":"Barlogie","year":"2001","journal-title":"Blood"},{"key":"2019111716545353200_B49","doi-asserted-by":"crossref","first-page":"5504","DOI":"10.1158\/1078-0432.CCR-05-0213","article-title":"A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma","volume":"11","author":"Prince","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2019111716545353200_B50","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2002.02.116","article-title":"Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma","volume":"20","author":"Rajkumar","year":"2002","journal-title":"J Clin Oncol"},{"key":"2019111716545353200_B51","first-page":"826","article-title":"First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma","volume":"89","author":"Cavo","year":"2004","journal-title":"Haematologica"},{"key":"2019111716545353200_B52","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/sj.thj.6200403","article-title":"Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma","volume":"5","author":"Palumbo","year":"2004","journal-title":"Hematol J"},{"key":"2019111716545353200_B53","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/sj.thj.6200401","article-title":"Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma","volume":"5","author":"Offidani","year":"2004","journal-title":"Hematol J"},{"key":"2019111716545353200_B54","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1080\/10428190600821955","article-title":"The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide - vincristine - doxorubicin - methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis","volume":"47","author":"Wu","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"2019111716545353200_B55","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/annonc\/mdh026","article-title":"Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study","volume":"15","author":"Zervas","year":"2004","journal-title":"Ann Oncol"},{"key":"2019111716545353200_B56","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1182\/blood-2002-01-0335","article-title":"Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy","volume":"100","author":"Zangari","year":"2002","journal-title":"Blood"},{"key":"2019111716545353200_B57","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","article-title":"Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"key":"2019111716545353200_B58","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1182\/blood-2006-01-0154","article-title":"Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis","volume":"108","author":"Zonder","year":"2006","journal-title":"Blood"},{"key":"2019111716545353200_B59","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1182\/blood-2008-02-141614","article-title":"Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure","volume":"112","author":"Wang","year":"2008","journal-title":"Blood"},{"key":"2019111716545353200_B60","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"2019111716545353200_B61","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1365-2141.2007.06538.x","article-title":"Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients","volume":"137","author":"Morgan","year":"2007","journal-title":"Br J Haematol"},{"key":"2019111716545353200_B62","first-page":"1498","article-title":"Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study","volume":"91","author":"Harousseau","year":"2006","journal-title":"Haematologica"},{"key":"2019111716545353200_B63","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1080\/10428190701647887","article-title":"Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma","volume":"48","author":"Niesvizky","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"2019111716545353200_B64","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/ajh.20382","article-title":"Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma","volume":"79","author":"Wang","year":"2005","journal-title":"Am J Hematol"},{"key":"2019111716545353200_B65","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1038\/sj.leu.2403533","article-title":"Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy","volume":"18","author":"Minnema","year":"2004","journal-title":"Leukemia"},{"key":"2019111716545353200_B66","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood-2006-03-013086","article-title":"Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma","volume":"108","author":"Offidani","year":"2006","journal-title":"Blood"},{"key":"2019111716545353200_B67","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJMoa053583","article-title":"Thalidomide and hematopoietic-cell transplantation for multiple myeloma","volume":"354","author":"Barlogie","year":"2006","journal-title":"N Engl J Med"},{"key":"2019111716545353200_B68","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","article-title":"Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"2019111716545353200_B69","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdl313","article-title":"Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy","volume":"17","author":"Baz","year":"2006","journal-title":"Ann Oncol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2010\/1\/437\/1493136\/bep00110000437.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2010\/1\/437\/1493136\/bep00110000437.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T05:30:05Z","timestamp":1712122205000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2010\/1\/437\/96384\/Thrombosis-in-Multiple-Myeloma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,4]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12,4]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2010.1.437","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,4]]}}}